CN115677617A - 一种靶向c-Src激酶SH3结构域的化合物及其应用 - Google Patents
一种靶向c-Src激酶SH3结构域的化合物及其应用 Download PDFInfo
- Publication number
- CN115677617A CN115677617A CN202211373706.3A CN202211373706A CN115677617A CN 115677617 A CN115677617 A CN 115677617A CN 202211373706 A CN202211373706 A CN 202211373706A CN 115677617 A CN115677617 A CN 115677617A
- Authority
- CN
- China
- Prior art keywords
- src
- protein
- medicament
- src kinase
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001332 SRC Human genes 0.000 title claims abstract description 41
- 108060006706 SRC Proteins 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 29
- 230000008685 targeting Effects 0.000 title claims abstract description 18
- 150000003384 small molecules Chemical class 0.000 claims abstract description 11
- 108010087686 src-Family Kinases Proteins 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 9
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 14
- 102000000395 SH3 domains Human genes 0.000 claims description 12
- 108050008861 SH3 domains Proteins 0.000 claims description 12
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- -1 amide compound Chemical class 0.000 abstract description 3
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 11
- 230000003197 catalytic effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102000014400 SH2 domains Human genes 0.000 description 5
- 108050003452 SH2 domains Proteins 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000009076 src-Family Kinases Human genes 0.000 description 5
- 235000002374 tyrosine Nutrition 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000001165 hydrophobic group Chemical group 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JEWSLNZBOLRFKI-UHFFFAOYSA-N n-[3-(4-bromophenyl)-1,2,4-thiadiazol-5-yl]-2-methylpropanamide Chemical compound S1C(NC(=O)C(C)C)=NC(C=2C=CC(Br)=CC=2)=N1 JEWSLNZBOLRFKI-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000002849 thermal shift Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
一种靶向c‑Src激酶SH3结构域的化合物及其应用摘要：本发明公开了一种式(I)所示的含有噻二唑结构的酰胺类化合物以及其作为新型的靶向c‑Src蛋白SH3结构域的Src激酶小分子抑制剂的应用。本发明还公开了(I)化合物在靶向c‑Src蛋白用于预防和/或治疗弥漫性大细胞淋巴瘤等肿瘤疾病方面的用途。
Description
技术领域
本发明属于医药领域，涉及一种靶向c-Src蛋白SH3结构域的化合物及其应用。具体地，本发明化合物具有式(Ⅰ)所示结构。本发明公开了所述化合物作为靶向c-Src蛋白用于预防和/或治疗弥漫性大细胞淋巴瘤等肿瘤疾病方面的用途。本发明化合物是通过靶向SH3结构域调控c-Src激酶活性的作用机制来发挥抗肿瘤活性的，故能够克服目前临床上通过靶向c-Src激酶催化结构域发挥抗肿瘤活性的药物的易引起肿瘤细胞耐药的缺陷。
背景技术
Src蛋白酪氨酸激酶家族成员包括Src、Lyn、Fyn、Yes、Lck、Blk和Hck，其中c-Src是影响细胞增殖、分化、运动和存活等一系列信号转导通路的中枢。Src的功能调控是通过在两个位点的酪氨酸磷酸化进行的，但具有相反作用。其中，Tyr416位点的磷酸化会上调Src的催化活性，而在羧基末端尾区，在Tyr527位点的磷酸化会降低Src的催化活性。激活后的c-Src参与到正常生理和癌症发生过程包括增殖、分化、生存率和血管生成等。
SRC作为一个经典的原癌基因，编码具有酪氨酸激酶活性的c-Src蛋白。已经有多篇研究报道，c-Src在多种人类肿瘤中处于高表达状态或具有高激酶活性，并参与到癌症发生发展的多个过程中，包括细胞增殖、分化、血管生成和预后生存率等，在来自结肠、肝脏、肺、乳腺和胰腺的肿瘤中，有超过50%的c-Src激活已被证实，此外，c-Src还能促进细胞增殖、迁移、侵袭和血管生成；大量研究证实蛋白酪氨酸激酶是治疗肿瘤的重要靶点。
目前，靶向Src蛋白催化结构域的ATP竞争性抑制剂已在临床上用于肿瘤治疗。但是肿瘤细胞极易对该类药物产生耐药性，这也是目前靶向c-Src蛋白催化结构域的抗肿瘤药物面临的主要问题。c-Src蛋白由四个Src同源结构域(SH4、SH3、SH2、SH1)组成。SH4结构域定位于N末端，包含锚定上膜的豆蔻酰化序列，因此靶向Src家族激酶到质膜上。SH3结构域结合富含脯氨酸残基的氨基酸序列，籍此对c-Src活性、细胞内定位和招募c-Src底物起到重要作用。SH2结构域结合包含磷酸化酪氨酸的短模体(motif)。SH2和SH3结构域共同协作调节Src家族激酶的催化活性。SH1(催化结构域)具有激酶活性在失活的构象中，人源c-Src 527位酪氨酸被磷酸化，和它自身的SH2结构域相互作用。这种作用使得SH3结构域和富含脯氨酸的linker结构域相互作用，使c-Src维持在一个紧密结合的失活状态。一旦酪氨酸527发生去磷酸化，分子内的相互作用使c-Src处于不稳定状态导致酪氨酸416的自身磷酸化。一系列的事件使得分子打开并且释放出SH2和SH3结构域，进而和其它受体酪氨酸激酶、G蛋白偶联受体和局部黏附激酶(FAK)等发生相互作用。该蛋白在SH3结构域和多聚脯氨酸-II(PPII)螺旋之间以及SH2结构域和C端磷酸化尾巴(CTPT)之间分别含有两个自结合肽(SBP)位点，这两个位点是抗癌药物调节激酶活性的潜在靶点。
传统非受体酪氨酸激酶药物多作用于激酶催化结构域如舒尼替尼、达沙替尼、尼洛替尼、伯舒替尼、凡德他尼等，易产生耐药性，而SH3结构域作为调节Src家族激酶的催化活性的重要部分，目前尚无相关靶向该位点的抗肿瘤药物上市。
发明内容
通过蛋白热迁移实验进行高通量筛选，发现了一种新型靶向Src蛋白SH3结构域的Src激酶小分子抑制剂；并测定了其对人B细胞淋巴瘤的抗细胞增殖活性。由此本发明的一个目的在于提供一种新型的靶向c-Src蛋白SH3结构域的Src激酶小分子抑制剂，式(Ⅰ)所示：
(Ⅰ)。
式(Ⅰ)所示化合物为靶向c-Src蛋白SH3结构域的抗肿瘤小分子先导化合物的发现提供了新的骨架，为设计新型靶向Src蛋白抗肿瘤药物提供了化学结构上的启示。
本发明的另一个目的在于提供式(Ⅰ)所示的化合物作为靶向Src蛋白在抗肿瘤中的用途。
式(Ⅰ)所示的化合物能够靶向c-Src蛋白SH3结构域并能有效抑制c-Src发生活化，从而抑制Src蛋白对细胞增殖、迁移、侵袭和血管生成促进活性。进而有效地预防和治疗与生发中心B细胞淋巴瘤相关的恶性淋巴瘤疾病。
附图说明
图1.化合物N-(3-(4-溴苯基)-1,2,4-噻二唑-5-基)-2-甲基-丙酰胺的结构式。
图2.化合物与SH3结构域蛋白热迁移实验曲线。
图3.化合物抑制弥漫大B细胞淋巴瘤细胞活性的IC50测定曲线。
图4.化合物的抗肿瘤细胞增殖活性。
具体实施方式
在本发明中，采用蛋白热迁移法对候选化合物进行高通量筛选，蛋白热迁移实验是确定小分子化合物与目标蛋白是否结合的方便可靠的实验方法，广泛应用于蛋白质与小分子结合的高通量筛选中。蛋白热迁移实验的基本原理是在目标蛋白的缓冲液中加入荧光染料，使用PCR仪器将体系的温度从25℃逐步提升到80℃，在升温过程中，目标蛋白的疏水基团会从内部暴露到表面，荧光染料与暴露的疏水基团结合的程度会变高，荧光信号会增加，达到最大值后荧光会逐渐淬灭信号会下降。通过玻尔兹曼方程拟合信号曲线可求出Tm(熔解温度)值，对应为蛋白半数解链时的温度。在体系中加入小分子后，如果小分子与蛋白结合，会使蛋白的稳定性增加，即对应Tm值升高，因此，加药组与对照组相比，熔解曲线会向右迁移。
本发明中，我们通过蛋白热迁移实验发现化合物N-(3-(4-溴苯基)-1,2,4-噻二唑-5-基)-2-甲基-丙酰胺与c-Src蛋白SH3结构域有结合。细胞水平的增殖抑制实验显示化合物80(45)对人B细胞淋巴瘤细胞系的DB细胞的抗细胞增殖活性较强，且具有剂量依赖性。
本发明提供了能够靶向c-Src蛋白SH3结构域的c-Src激酶的小分子抑制剂，以及其对B细胞淋巴瘤细胞增殖的影响。
本发明的化合物Ⅰ是通过与c-Src蛋白SH3结构域结合发挥肿瘤细胞增殖抑制活性。
下面结合具体实施例对本发明作进一步阐述，这些实施例并非限制性的，而仅作为示例说明本发明。
实施例1：蛋白质的表达和纯化。
将Src-SH3构建于Rosetta(DE3)表达载体上，载体表达的融合蛋白带有N端Trx标签和His标签，在16℃表达重组蛋白，收集菌株，超声，离心(18000 rpm, 30 min, 4℃)，取上清液。用镍亲和层析色谱(GE Healthcare)纯化蛋白质，将蛋白洗脱液收集测定浓度后，根据其浓度加入thrombin，在25℃下酶切12-16小时，次晨，以3Kd的浓缩管离心浓缩，将蛋白用蠕动泵过镍柱，穿出液即为目的蛋白。蛋白质储存在含有20mM Tris PH8.0，100mMNacl的缓冲液中。
实施例2：蛋白热迁移实验（Protein thermal shift assay)检测小分子与蛋白的结合。
蛋白质通常以native状态存在，加热会导致蛋白质转化为 Denatured状态，暴露出疏水基团。暴露出的疏水基团可以与荧光染料SYPRO Orange相结合，从而提高荧光染料的发射光，于是可以通过检测荧光强度来反映蛋白质的稳定性。从100 mM母液制备一系列稀释浓度的待测化合物。分别加入buffer缓冲液(20mM Tris PH8.0，100mM Nacl)、c-SRCSH3蛋白、待测化合物、 50×荧光染料构成20μL反应体系，为防止蛋白变性全程保持低温进行操作，使用Bio-rad 荧光定量PCR，以1%升温速率，将体系温度从25℃逐渐升温至 80℃，同时以20秒为间隔记录荧光强度随温度的变化情况。进一步，在Bio-Rad CFX程序中，利用Boltzmann拟合方法，计算化合物不同浓度条件下SH3的熔解温度(Tm)。
实施例3：体外细胞活性分析实验检验化合物对c-Src活性抑制引起的DB癌细胞增殖活性的影响。
在含有10%胎牛血清（FBS）和1%青霉素/链霉素的RPMI 1640培养基中，培养指数生长的细胞，以每孔2 x 104个细胞的密度接种于96孔板，使用6.25μM和1.5625μM的苗头化合物孵育细胞。孵育三天后，用Cell Counting Kit-8(CCK8)检测细胞活性，实验结果见图3、图4。结果表明化合物80(45)对DB细胞表现出剂量依赖性抗增殖活性。我们的工作为发现更多的c-Src抑制剂的提供了新的骨架，并为克服目前临床上通过靶向c-Src激酶催化结构域发挥抗肿瘤活性的药物的易引起肿瘤细胞耐药的缺陷提供了新的思路。
Claims (7)
1.一种c-Src激酶小分子抑制剂，结构式如图1所示。
2.包含式I所示的化合物、或其药学上可接受的盐和药学上可接受的载体的药物组合物在制备预防和/或治疗弥漫性大细胞淋巴瘤相关的疾病的药物中的应用。
3.根据权利要求2所述的应用，其特征在于，预防和/或治疗弥漫性大细胞淋巴瘤相关的疾病的药物为c-Src蛋白SH3结构域的Src激酶小分子抑制剂的药物。
4.包含式I所示的化合物、或其药学上可接受的盐和药学上可接受的载体的药物组合物在制备预防和/或治疗Src激酶活性异常相关的疾病的药物中的应用。
5.根据权利要求4所述的应用，其特征在于，预防和/或治疗Src激酶活性异常相关的疾病的药物为Src激酶小分子抑制剂的药物。
6.包含式I所示的化合物、或其药学上可接受的盐和药学上可接受的载体的药物组合物在制备预防和/或治疗B细胞淋巴瘤相关的恶性淋巴瘤相关的疾病的药物中的应用。
7.根据权利要求6所述的应用，其特征在于，预防和/或治疗B细胞淋巴瘤相关的恶性淋巴瘤相关的疾病的药物为通过靶向SH3结构域调控c-Src激酶活性的作用机制来发挥抗肿瘤活性的药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211373706.3A CN115677617B (zh) | 2022-11-04 | 2022-11-04 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211373706.3A CN115677617B (zh) | 2022-11-04 | 2022-11-04 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115677617A true CN115677617A (zh) | 2023-02-03 |
| CN115677617B CN115677617B (zh) | 2023-12-26 |
Family
ID=85048135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211373706.3A Active CN115677617B (zh) | 2022-11-04 | 2022-11-04 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115677617B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002083668A1 (en) * | 2001-04-10 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Isoxaxole derivatives as inhibitors of src and other protein kinases |
| CN103788085A (zh) * | 2012-10-31 | 2014-05-14 | 复旦大学 | 2-（喹唑啉-4-氨基）-5-噻唑甲酰胺类衍生物及其生物药物用途 |
| CN107296807A (zh) * | 2016-04-15 | 2017-10-27 | 中国科学院上海生命科学研究院 | Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
-
2022
- 2022-11-04 CN CN202211373706.3A patent/CN115677617B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002083668A1 (en) * | 2001-04-10 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Isoxaxole derivatives as inhibitors of src and other protein kinases |
| CN103788085A (zh) * | 2012-10-31 | 2014-05-14 | 复旦大学 | 2-（喹唑啉-4-氨基）-5-噻唑甲酰胺类衍生物及其生物药物用途 |
| CN107296807A (zh) * | 2016-04-15 | 2017-10-27 | 中国科学院上海生命科学研究院 | Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
Non-Patent Citations (1)
| Title |
|---|
| ACS: "RN:898623-21-7化合物", 《STN REGISTRY数据库》, pages 898623 - 21 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115677617B (zh) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Johnson | The regulation of protein phosphorylation | |
| Vlach et al. | Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 | |
| Ingley | Src family kinases: regulation of their activities, levels and identification of new pathways | |
| Concha et al. | Long-range inhibitor-induced conformational regulation of human IRE1α endoribonuclease activity | |
| Zhang et al. | Generation and validation of intracellular ubiquitin variant inhibitors for USP7 and USP10 | |
| Graeser et al. | Regulation of the CDK-related protein kinase PCTAIRE-1 and its possible role in neurite outgrowth in Neuro-2A cells | |
| US20110269141A1 (en) | Target protein and target gene for drug discovery, and screening method | |
| Zhang et al. | The substrate binding domains of human SIAH E3 ubiquitin ligases are now crystal clear | |
| Shen et al. | Phosphorylation modulates direct interactions between the Toll receptor, Pelle kinase and Tube | |
| Kirken et al. | Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells | |
| Kim et al. | Toxoplasma gondii GRA8-derived peptide immunotherapy improves tumor targeting of colorectal cancer | |
| Lei et al. | Current progress and novel strategies that target CDK12 for drug discovery | |
| Jiang et al. | Targeting the N terminus of eIF4AI for inhibition of its catalytic recycling | |
| Nie et al. | Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy | |
| Zhang et al. | Targeting death-associated protein kinases for treatment of human diseases: recent advances and future directions | |
| Aicart-Ramos et al. | Protein kinase D activity controls endothelial nitric oxide synthesis | |
| CN115677617A (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 | |
| CN115716820B (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 | |
| Araujo-Abad et al. | The intrinsically disordered, epigenetic factor RYBP binds to the citrullinating enzyme PADI4 in cancer cells | |
| CN116178358B (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 | |
| CN117069657B (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 | |
| Luo et al. | ABL1 and Cofilin1 promote T-cell acute lymphoblastic leukemia cell migration | |
| Lodewick et al. | Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model | |
| Bae et al. | Chemical regulation of signaling pathways to programmed necrosis | |
| CN117069657A (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |